SYRS Insider Trading
Insider Ownership Percentage: 12.26%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Syros Pharmaceuticals Share Price & Price History
Current Price: $0.00
Price Change: ▲ Price Increase of +0.0002 (100.00%)
As of 04/10/2026 03:42 PM ET
Syros Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/2/2024 | Nancy A Simonian | Director | Sell | 37,070 | $0.27 | $10,008.90 | 4,000 |  |
| 11/25/2024 | Nancy A Simonian | Director | Sell | 134,713 | $0.27 | $36,372.51 | 41,070 | |
| 9/12/2024 | Jason Haas | CFO | Buy | 45,344 | $1.68 | $76,177.92 | 124,552 | |
| 9/10/2024 | Conley Chee | CEO | Buy | 50,000 | $1.51 | $75,500.00 | 72,504 | |
| 9/10/2024 | Jason Haas | CFO | Buy | 35,363 | $1.55 | $54,812.65 | 59,915 | |
| 6/28/2024 | Richard A Young | Director | Sell | 34,837 | $5.12 | $178,365.44 | 8,000 | |
| 4/2/2024 | David Roth | Insider | Sell | 150 | $4.98 | $747.00 | 10,451 | |
| 12/21/2023 | Srinivas Akkaraju | Director | Buy | 904,977 | $4.42 | $3,999,998.34 | 1,786,427 | |
| 12/6/2023 | David Roth | Insider | Sell | 6,287 | $3.95 | $24,833.65 | 6,287 | |
| 7/31/2023 | David Roth | Insider | Sell | 7,348 | $3.95 | $29,024.60 | | |
| 7/17/2023 | Eric R. Olson | Insider | Sell | 689 | $3.50 | $2,411.50 | 6,661 | |
Syros Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/14/2025 | Two Sigma Securities LLC | 107,742 | $25K | 0.0% | N/A | 0.402% |  |
| 12/13/2024 | Exome Asset Management LLC | 298,575 | $0.64M | 0.4% | +87.6% | 1.113% | |
| 11/14/2024 | Walleye Capital LLC | 86,641 | $0.19M | 0.0% | -69.7% | 0.323% | |
| 11/5/2024 | GSA Capital Partners LLP | 15,905 | $34K | 0.0% | N/A | 0.059% | |
| 8/9/2024 | Renaissance Technologies LLC | 117,435 | $0.61M | 0.0% | -2.0% | 0.438% | |
| 8/6/2024 | Certuity LLC | 21,202 | $0.11M | 0.0% | N/A | 0.079% | |
| 8/6/2024 | Acadian Asset Management LLC | 34,578 | $0.18M | 0.0% | +101.5% | 0.129% | |
| 7/18/2024 | Assenagon Asset Management S.A. | 15,873 | $82K | 0.0% | -90.7% | 0.059% | |
| 5/29/2024 | Opaleye Management Inc. | 787,545 | $4.21M | 0.9% | +119.1% | 2.947% | |
| 5/20/2024 | Virtu Financial LLC | 12,030 | $64K | 0.0% | N/A | 0.045% | |
| 5/16/2024 | Kennedy Capital Management LLC | 404,914 | $2.17M | 0.0% | N/A | 1.515% | |
| 5/10/2024 | Acadian Asset Management LLC | 17,162 | $91K | 0.0% | N/A | 0.064% | |
| 5/10/2024 | Vanguard Group Inc. | 928,046 | $4.97M | 0.0% | +21.3% | 3.472% | |
| 4/24/2024 | Assenagon Asset Management S.A. | 169,999 | $0.91M | 0.0% | +576.5% | 0.636% | |
| 2/15/2024 | Opaleye Management Inc. | 359,370 | $2.80M | 0.7% | N/A | 1.706% | |
| 2/15/2024 | Flagship Pioneering Inc. | 1,293,848 | $10.08M | 0.8% | +30.2% | 6.141% | |
| 2/14/2024 | Avidity Partners Management LP | 1,673,538 | $13.04M | 0.5% | +5.8% | 7.943% | |
| 2/13/2024 | Bain Capital Life Sciences Investors LLC | 2,749,808 | $21.42M | 2.1% | +29.4% | 13.051% | |
| 11/14/2023 | Avidity Partners Management LP | 1,581,142 | $6.25M | 0.3% | +8.0% | 7.635% | |
| 11/13/2023 | CHI Advisors LLC | 1,299,359 | $5.12M | 1.5% | +69.3% | 6.274% | |
| 11/6/2023 | Assenagon Asset Management S.A. | 25,130 | $99K | 0.0% | +142.2% | 0.121% | |
| 10/19/2023 | Clarius Group LLC | 18,620 | $74K | 0.0% | N/A | 0.090% | |
| 8/14/2023 | Shay Capital LLC | 26,426 | $83K | 0.0% | +87.3% | 0.128% | |
| 8/11/2023 | ExodusPoint Capital Management LP | 118,398 | $0.37M | 0.0% | -2.6% | 0.572% | |
| 5/16/2023 | Ally Bridge Group NY LLC | 249,126 | $0.67M | 0.9% | -71.3% | 1.210% | |
| 5/11/2023 | CHI Advisors LLC | 767,445 | $2.05M | 0.5% | N/A | 3.760% | |
| 4/18/2023 | Assenagon Asset Management S.A. | 10,376 | $28K | 0.0% | N/A | 0.051% | |
| 2/9/2023 | Denali Advisors LLC | 7,700 | $28K | 0.0% | N/A | 0.038% | |
| 11/15/2022 | Flagship Pioneering Inc. | 993,848 | $6.40M | 0.3% | -66.2% | 15.775% | |
| 11/15/2022 | Bain Capital Life Sciences Investors LLC | 1,082,404 | $6.97M | 0.8% | -82.7% | 17.181% | |
| 11/9/2022 | Edmond DE Rothschild Holding S.A. | 4,382 | $28K | 0.0% | N/A | 0.070% | |
| 10/24/2022 | Clarius Group LLC | 19,347 | $0.13M | 0.0% | -90.0% | 0.307% | |
| 10/13/2022 | LGT Capital Partners LTD. | 55,000 | $0.35M | 0.0% | -90.0% | 0.873% | |
| 8/11/2022 | Artal Group S.A. | 4,000,000 | $3.85M | 0.2% | +14.3% | 6.367% | |
| 8/10/2022 | Clarius Group LLC | 193,483 | $0.19M | 0.0% | N/A | 0.308% | |
| 7/19/2022 | Sawtooth Solutions LLC | 42,286 | $41K | 0.0% | +76.5% | 0.067% | |
| 7/13/2022 | LGT Capital Partners LTD. | 550,000 | $0.53M | 0.0% | +10.0% | 0.876% | |
| 7/13/2022 | Private Advisor Group LLC | 51,437 | $50K | 0.0% | +112.9% | 0.082% | |
| 5/16/2022 | Ally Bridge Group NY LLC | 3,364,895 | $4M | 3.0% | -4.9% | 5.420% | |
| 5/12/2022 | Artal Group S.A. | 3,500,000 | $4.17M | 0.2% | +16.7% | 5.638% | |
| 5/12/2022 | Connor Clark & Lunn Investment Management Ltd. | 137,156 | $0.16M | 0.0% | +15.6% | 0.221% | |
| 5/11/2022 | ACT Capital Management LLC | 35,000 | $42K | 0.0% | +62.8% | 0.056% | |
| 5/11/2022 | GSA Capital Partners LLP | 372,208 | $0.44M | 0.1% | +53.7% | 0.600% | |
| 2/15/2022 | Adage Capital Partners GP L.L.C. | 1,900,000 | $6.19M | 0.0% | +5.6% | 3.067% | |
| 2/14/2022 | Altium Capital Management LP | 1,160,000 | $3.78M | 1.0% | -8.8% | 1.873% | |
| 2/14/2022 | GSA Capital Partners LLP | 242,132 | $0.79M | 0.1% | +119.4% | 0.391% | |
| 2/14/2022 | Ally Bridge Group NY LLC | 3,539,895 | $11.54M | 4.0% | +2.9% | 5.714% | |
| 2/11/2022 | Ensign Peak Advisors Inc | 45,000 | $0.15M | 0.0% | -55.0% | 0.073% | |
| 2/10/2022 | Connor Clark & Lunn Investment Management Ltd. | 118,632 | $0.39M | 0.0% | +14.8% | 0.192% | |
| 2/7/2022 | SG Americas Securities LLC | 12,012 | $39K | 0.0% | -61.4% | 0.019% | |
| 2/3/2022 | ACT Capital Management LLC | 21,500 | $70K | 0.1% | -59.0% | 0.035% | |
Data available starting January 2016
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Read More on Syros Pharmaceuticals
Volume
1,401 shs
Average Volume
23,495 shs
Market Capitalization
$10.73 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.31
Who are the company insiders with the largest holdings of Syros Pharmaceuticals?
Syros Pharmaceuticals' top insider shareholders include:
- Srinivas Akkaraju (Director)
- Richard A Young (Director)
- Jason Haas (CFO)
- Conley Chee (CEO)
- Nancy A Simonian (Director)
- Jeremy P Springhorn (Insider)
- Eric R Olson (Insider)
- Timothy Tyson (Director)
- David Roth (Insider)
- Mark J Alles (Director)
Learn More about top insider investors at Syros Pharmaceuticals.
Syros Pharmaceuticals Active Insiders
